多发性骨髓瘤治疗现状及方向

Current Situation and Direction of Treatment for Multiple Myeloma

多发性骨髓瘤(multiple myeloma,MM)系骨髓浆细胞源性恶性肿瘤,单克隆性浆细胞恶性增值侵犯骨骼及软组织,可引起高钙血症、贫血、骨痛、肺部感染等一系列临床表现。该病发病率较高,约占恶性血液肿瘤第二高发疾病。近年来随新型免疫调节剂、造血干细胞移植技术、嵌合抗原受体T细胞免疫疗法及外科干预等治疗手段的开展,在提高患者生活质量和延长患者的无进展生存期(PFS)、总生存期(OS)等方面效果显著。但本病仍是无法治愈的疾病,目前针对MM的治疗主要是延缓疾病的复发、进展及提高生活质量。文章将综述近年来MM的一些治疗进展,旨在为MM治疗提供更好的参考。

Multiple myeloma is a myeloid cell-derived malignant tumor.Malignant proliferation of monoclonal plasma cells can invade bones and soft tissues,causing a series of clinical manifestations such as hypercalcemia,anemia,bone pain,and pulmonary infection.The incidence rate is ranked second in all hematological malignancies.In recent years,with the improvement of treatment methods,such as new immunomodulators,hematopoietic stem cell transplantation technology,chimeric antigen receptor T cell immunotherapy,nanoparticle technology and surgical interventions,the quality of life of patients and the progression free survival of patients are prolonged.Survival and other aspects have significant effects.However,the disease is still an incurable disease.The current treatment for MM is mainly to delay the recurrence,progression and improve the quality of life.This article will review some of the treatment advances of MM in recent years,aiming to provide a better reference for MM treatment.